Jump to content

Johann Bauersachs: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
self promotion remove
Tags: references removed Visual edit
rewriting
Tags: references removed Visual edit
Line 8: Line 8:
| death_date =
| death_date =
| death_place =
| death_place =
| residence = [[Germany]]
| citizenship =
| citizenship =
| nationality = [[Germany|German]]
| nationality = [[Germany|German]]
Line 27: Line 26:
Prof. Dr. Johann Bauersachs is a German internist, cardiologist, and full professor at the [[Hannover Medical School]].<ref>{{Cite web |title=Medizinische Hochschule Hannover : Department of Cardiology und Angiology |url=https://www.mhh.de/en/mhh-clinical-departments/department-of-cardiology-und-angiology |access-date=2022-03-22 |website=www.mhh.de}}</ref> He is widely recognized for his scholarly contributions to the domains of [[acute coronary syndrome]], left ventricular repair and remodelling following [[ischemia]], and acute and [[chronic heart failure]].<ref>{{Cite journal |last=Harjola |first=Veli‐Pekka |last2=Parissis |first2=John |last3=Bauersachs |first3=Johann |last4=Brunner‐La Rocca |first4=Hans‐Peter |last5=Bueno |first5=Hector |last6=Čelutkienė |first6=Jelena |last7=Chioncel |first7=Ovidiu |last8=Coats |first8=Andrew J.S. |last9=Collins |first9=Sean P. |last10=Boer |first10=Rudolf A. |last11=Filippatos |first11=Gerasimos |date=2020-04-29 |title=Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |url=https://doi.org/10.1002/ejhf.1831 |journal=European Journal of Heart Failure |volume=22 |issue=8 |pages=1298–1314 |doi=10.1002/ejhf.1831 |issn=1388-9842}}</ref><ref>{{Cite journal |last=Collet |first=Jean-Philippe |last2=Thiele |first2=Holger |last3=Barbato |first3=Emanuele |last4=Barthélémy |first4=Olivier |last5=Bauersachs |first5=Johann |last6=Bhatt |first6=Deepak L. |last7=Dendale |first7=Paul |last8=Dorobantu |first8=Maria |last9=Edvardsen |first9=Thor |last10=Folliguet |first10=Thierry |last11=Gale |first11=Chris P. |date=2021-04-07 |title=2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation |url=https://pubmed.ncbi.nlm.nih.gov/32860058 |journal=European Heart Journal |volume=42 |issue=14 |pages=1289–1367 |doi=10.1093/eurheartj/ehaa575 |issn=1522-9645 |pmid=32860058}}</ref><ref>{{Cite journal |last=Schäfer |first=Andreas |last2=Bauersachs |first2=Johann |date=2021-11-03 |title=P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention – Understanding the debate on Prasugrel or Ticagrelor |url=https://www.sciencedirect.com/science/article/pii/S016372582100231X |journal=Pharmacology & Therapeutics |language=en |pages=108029 |doi=10.1016/j.pharmthera.2021.108029 |issn=0163-7258}}</ref><ref>{{Cite journal |last=Harjola |first=Veli-Pekka |last2=Parissis |first2=John |last3=Bauersachs |first3=Johann |last4=Rocca |first4=Hans-Peter Brunner-La |last5=Bueno |first5=Hector |last6=Celutkiene |first6=Jelena |last7=Chioncel |first7=Ovidiu |last8=Coats |first8=Andrew J. S. |last9=Collins |first9=Sean P. |last10=Boer |first10=Rudolf A. de |last11=Filippatos |first11=Gerasimos |date=2020-08-01 |title=Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |url=https://research.rug.nl/en/publications/acute-coronary-syndromes-and-acute-heart-failure-a-diagnostic-dil |journal=European Journal of Heart Failure |language=English |issue=8 |pages=1298–1314 |doi=10.1002/ejhf.1831 |issn=1388-9842}}</ref><ref>{{Cite journal |last=Harjola |first=Veli Pekka |last2=Parissis |first2=John |last3=Bauersachs |first3=Johann |last4=Rocca |first4=Hans Peter Brunner-La |last5=Bueno |first5=Hector |last6=Čelutkienė |first6=Jelena |last7=Chioncel |first7=Ovidiu |last8=Coats |first8=Andrew J. S. |last9=Collins |first9=Sean P. |last10=Boer |first10=Rudolf A. de |last11=Filippatos |first11=Gerasimos |date=2020-04-29 |title=Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |url=https://pure.qub.ac.uk/en/publications/acute-coronary-syndromes-and-acute-heart-failure-a-diagnostic-dil |journal=European Journal of Heart Failure |language=English |doi=10.1002/ejhf.1831 |issn=1388-9842 |pmid=32347648}}</ref>
Prof. Dr. Johann Bauersachs is a German internist, cardiologist, and full professor at the [[Hannover Medical School]].<ref>{{Cite web |title=Medizinische Hochschule Hannover : Department of Cardiology und Angiology |url=https://www.mhh.de/en/mhh-clinical-departments/department-of-cardiology-und-angiology |access-date=2022-03-22 |website=www.mhh.de}}</ref> He is widely recognized for his scholarly contributions to the domains of [[acute coronary syndrome]], left ventricular repair and remodelling following [[ischemia]], and acute and [[chronic heart failure]].<ref>{{Cite journal |last=Harjola |first=Veli‐Pekka |last2=Parissis |first2=John |last3=Bauersachs |first3=Johann |last4=Brunner‐La Rocca |first4=Hans‐Peter |last5=Bueno |first5=Hector |last6=Čelutkienė |first6=Jelena |last7=Chioncel |first7=Ovidiu |last8=Coats |first8=Andrew J.S. |last9=Collins |first9=Sean P. |last10=Boer |first10=Rudolf A. |last11=Filippatos |first11=Gerasimos |date=2020-04-29 |title=Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |url=https://doi.org/10.1002/ejhf.1831 |journal=European Journal of Heart Failure |volume=22 |issue=8 |pages=1298–1314 |doi=10.1002/ejhf.1831 |issn=1388-9842}}</ref><ref>{{Cite journal |last=Collet |first=Jean-Philippe |last2=Thiele |first2=Holger |last3=Barbato |first3=Emanuele |last4=Barthélémy |first4=Olivier |last5=Bauersachs |first5=Johann |last6=Bhatt |first6=Deepak L. |last7=Dendale |first7=Paul |last8=Dorobantu |first8=Maria |last9=Edvardsen |first9=Thor |last10=Folliguet |first10=Thierry |last11=Gale |first11=Chris P. |date=2021-04-07 |title=2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation |url=https://pubmed.ncbi.nlm.nih.gov/32860058 |journal=European Heart Journal |volume=42 |issue=14 |pages=1289–1367 |doi=10.1093/eurheartj/ehaa575 |issn=1522-9645 |pmid=32860058}}</ref><ref>{{Cite journal |last=Schäfer |first=Andreas |last2=Bauersachs |first2=Johann |date=2021-11-03 |title=P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention – Understanding the debate on Prasugrel or Ticagrelor |url=https://www.sciencedirect.com/science/article/pii/S016372582100231X |journal=Pharmacology & Therapeutics |language=en |pages=108029 |doi=10.1016/j.pharmthera.2021.108029 |issn=0163-7258}}</ref><ref>{{Cite journal |last=Harjola |first=Veli-Pekka |last2=Parissis |first2=John |last3=Bauersachs |first3=Johann |last4=Rocca |first4=Hans-Peter Brunner-La |last5=Bueno |first5=Hector |last6=Celutkiene |first6=Jelena |last7=Chioncel |first7=Ovidiu |last8=Coats |first8=Andrew J. S. |last9=Collins |first9=Sean P. |last10=Boer |first10=Rudolf A. de |last11=Filippatos |first11=Gerasimos |date=2020-08-01 |title=Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |url=https://research.rug.nl/en/publications/acute-coronary-syndromes-and-acute-heart-failure-a-diagnostic-dil |journal=European Journal of Heart Failure |language=English |issue=8 |pages=1298–1314 |doi=10.1002/ejhf.1831 |issn=1388-9842}}</ref><ref>{{Cite journal |last=Harjola |first=Veli Pekka |last2=Parissis |first2=John |last3=Bauersachs |first3=Johann |last4=Rocca |first4=Hans Peter Brunner-La |last5=Bueno |first5=Hector |last6=Čelutkienė |first6=Jelena |last7=Chioncel |first7=Ovidiu |last8=Coats |first8=Andrew J. S. |last9=Collins |first9=Sean P. |last10=Boer |first10=Rudolf A. de |last11=Filippatos |first11=Gerasimos |date=2020-04-29 |title=Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology |url=https://pure.qub.ac.uk/en/publications/acute-coronary-syndromes-and-acute-heart-failure-a-diagnostic-dil |journal=European Journal of Heart Failure |language=English |doi=10.1002/ejhf.1831 |issn=1388-9842 |pmid=32347648}}</ref>


== Education ==
== Scientific Contributions==
His research interests include the [[pathogenesis]] and therapy of [[peripartum cardiomyopathy]], as well as in the mechanisms mediated by [[aldosterone]] and [[mineralocorticoid]] receptors and the involvement of non-coding RNAs.<ref>{{Cite journal |last=Hilfiker-Kleiner |first=Denise |last2=Haghikia |first2=Arash |last3=Nonhoff |first3=Justus |last4=Bauersachs |first4=Johann |date=2015-05-07 |title=Peripartum cardiomyopathy: current management and future perspectives |url=https://doi.org/10.1093/eurheartj/ehv009 |journal=European Heart Journal |volume=36 |issue=18 |pages=1090–1097 |doi=10.1093/eurheartj/ehv009 |issn=0195-668X |pmc=PMC4422973 |pmid=25636745}}</ref><ref>{{Cite journal |last=Bauersachs |first=Johann |last2=König |first2=Tobias |last3=van der Meer |first3=Peter |last4=Petrie |first4=Mark C. |last5=Hilfiker-Kleiner |first5=Denise |last6=Mbakwem |first6=Amam |last7=Hamdan |first7=Righab |last8=Jackson |first8=Alice M. |last9=Forsyth |first9=Paul |last10=de Boer |first10=Rudolf A. |last11=Mueller |first11=Christian |date=2019-07 |title=Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy |url=https://pubmed.ncbi.nlm.nih.gov/31243866/ |journal=European Journal of Heart Failure |volume=21 |issue=7 |pages=827–843 |doi=10.1002/ejhf.1493 |issn=1879-0844 |pmid=31243866}}</ref>
Research activities of Bauersachs focused initially on endothelial dependent dilatation which is crucial for the regulation of blood pressure and organ perfusion, and especially the characterisation of nitric oxide (NO) dependent and independent endothelial factors.<ref name="B1">Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996</ref> Supported by research grants from the [[Deutsche Forschungsgemeinschaft]] (DFG) ad personam and within special research programs (SFBs 355 und 688 at Wuerzburg University) he investigated endothelial dysfunction in heart failure, and myocardial remodeling after experimental myocardial infarction in rats and mice. He could demonstrate the importance of vascular oxidative stress for abnormal endothelial function in heart failure.<ref name="B2">Bauersachs J, Bouloumié A, Fraccarollo D, Hu K, Busse R, Ertl G Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 1999 Jul 20;100(3):292-8</ref> His group showed the attenuation of left ventricular remodeling after myocardial infarction by treatment with statins, the mineralocorticoid receptor (MR) antagonist Eplerenone and a novel enhancer of endothelial NO synthase.<ref name="B3">Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001</ref><ref name="B4">Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003 Nov 5;42(9):1666-73.</ref><ref name="B5">Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008). Improvement of left ventricular remodelling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118, 818-82.</ref> The importance of the MR for early healing and remodeling after myocardial infarction was demonstrated by treatment with MR antagonists, but also by cell specific MR deletion.<ref name="B6">Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G, Bauersachs J (2008). Immediate Mineralocorticoid Receptor Blockade After Myocardial Infarction Improves Infarct Healing by Modulation of the Inflammatory Response. Hypertension 51, 1-10</ref><ref name="B7">Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, Bauersachs J (2011). Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 32, 1275-86.</ref><ref name="B8">Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400-408.</ref> These research activities were the basis for clinical trials to improve MR antagonist therapy in patients with myocardial infarction, heart failure and renal dysfunction.<ref name="B9">Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J. 2013 Aug;34(31):2426-8. doi: 10.1093/eurheartj/eht235</ref><ref name="B10">Bauersachs J, Jaisser F, Toto R (2015). Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension 65, 257-263.</ref>


Together with T. Thum, Bauersachs published research on the role of non-coding RNA, especially microRNA, for cardiovascular diseases,<ref name="B11">Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267.</ref><ref name="B12">Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, Bauersachs J*, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984. *joint senior authors</ref><ref name="B13">Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. Circ Res 109, 334-47.</ref> that also led to several patents. The importance of microRNAs for fetal reprogramming of gene expression in heart failure was demonstrated,<ref name="B11" /> as well as the treatment using a so-called Antagomir in a mouse model of heart failure.<ref name="B12" />
Together with T. Thum, Bauersachs published research on the role of non-coding RNA, especially microRNA, for cardiovascular diseases,<ref name="B11">Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267.</ref><ref name="B12">Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, Bauersachs J*, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984. *joint senior authors</ref><ref name="B13">Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. Circ Res 109, 334-47.</ref> that also led to several patents. The importance of microRNAs for fetal reprogramming of gene expression in heart failure was demonstrated,<ref name="B11" /> as well as the treatment using a so-called Antagomir in a mouse model of heart failure.<ref name="B12" />

Revision as of 05:46, 26 March 2022

Johann Bauersachs
Born (1966-04-22) 22 April 1966 (age 58)
Karlsruhe
NationalityGerman
Known foracute coronary syndrome, left ventricular healing and remodeling after ischemia as well as acute and chronic heart failure.
Scientific career
Fieldsinternal medicine, cardiology, intensive care
InstitutionsHannover Medical School

Prof. Dr. Johann Bauersachs is a German internist, cardiologist, and full professor at the Hannover Medical School.[1] He is widely recognized for his scholarly contributions to the domains of acute coronary syndrome, left ventricular repair and remodelling following ischemia, and acute and chronic heart failure.[2][3][4][5][6]

Scientific Contributions

His research interests include the pathogenesis and therapy of peripartum cardiomyopathy, as well as in the mechanisms mediated by aldosterone and mineralocorticoid receptors and the involvement of non-coding RNAs.[7][8]

Together with T. Thum, Bauersachs published research on the role of non-coding RNA, especially microRNA, for cardiovascular diseases,[9][10][11] that also led to several patents. The importance of microRNAs for fetal reprogramming of gene expression in heart failure was demonstrated,[9] as well as the treatment using a so-called Antagomir in a mouse model of heart failure.[10]

These research activities are continued within the DFG cluster of excellence REBIRTH („From Regenerative Biology to Reconstructive Therapy“)[12][13] at Medical School Hannover with special emphasis on translation to clinical application. Bauersachs is chair of two clinical trials funded by the German Ministry of Research and Education (BMBF) in patients with heart failure: the study investigating the efficacy of Bromocriptine on left ventricular function in women with peripartal cardiomyopathy (PPCM)[14][15][16] and the large endpoint trial DIGIT-HF (DIGitoxin to Improve ouTcomes in patients with advanced chronic systolic Heart Failure; EudraCT No: 2013-005326-38).[17]

Memberships

Dr. Johann Bauersachs was awarded the Oskar-Lapp Award (2001) and the Albert-Fraenkel-Award (2004) from the German cardiac Society.[18] In 20018, he received the Paul-Morawitz Award from the same society.[19] Also, in the year 2006, he received the Parmley-Award from the American college of cardiology.[20] His additional awards include the Bernard and Joan Marshall Distinguished Investigator Award (2012). He served as a President of ESAC Germany (European Section of Aldosterone Council) Association.

Publications

References

  1. ^ "Medizinische Hochschule Hannover : Department of Cardiology und Angiology". www.mhh.de. Retrieved 2022-03-22.
  2. ^ Harjola, Veli‐Pekka; Parissis, John; Bauersachs, Johann; Brunner‐La Rocca, Hans‐Peter; Bueno, Hector; Čelutkienė, Jelena; Chioncel, Ovidiu; Coats, Andrew J.S.; Collins, Sean P.; Boer, Rudolf A.; Filippatos, Gerasimos (2020-04-29). "Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology". European Journal of Heart Failure. 22 (8): 1298–1314. doi:10.1002/ejhf.1831. ISSN 1388-9842.
  3. ^ Collet, Jean-Philippe; Thiele, Holger; Barbato, Emanuele; Barthélémy, Olivier; Bauersachs, Johann; Bhatt, Deepak L.; Dendale, Paul; Dorobantu, Maria; Edvardsen, Thor; Folliguet, Thierry; Gale, Chris P. (2021-04-07). "2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation". European Heart Journal. 42 (14): 1289–1367. doi:10.1093/eurheartj/ehaa575. ISSN 1522-9645. PMID 32860058.
  4. ^ Schäfer, Andreas; Bauersachs, Johann (2021-11-03). "P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention – Understanding the debate on Prasugrel or Ticagrelor". Pharmacology & Therapeutics: 108029. doi:10.1016/j.pharmthera.2021.108029. ISSN 0163-7258.
  5. ^ Harjola, Veli-Pekka; Parissis, John; Bauersachs, Johann; Rocca, Hans-Peter Brunner-La; Bueno, Hector; Celutkiene, Jelena; Chioncel, Ovidiu; Coats, Andrew J. S.; Collins, Sean P.; Boer, Rudolf A. de; Filippatos, Gerasimos (2020-08-01). "Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology". European Journal of Heart Failure (8): 1298–1314. doi:10.1002/ejhf.1831. ISSN 1388-9842.
  6. ^ Harjola, Veli Pekka; Parissis, John; Bauersachs, Johann; Rocca, Hans Peter Brunner-La; Bueno, Hector; Čelutkienė, Jelena; Chioncel, Ovidiu; Coats, Andrew J. S.; Collins, Sean P.; Boer, Rudolf A. de; Filippatos, Gerasimos (2020-04-29). "Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology". European Journal of Heart Failure. doi:10.1002/ejhf.1831. ISSN 1388-9842. PMID 32347648.
  7. ^ Hilfiker-Kleiner, Denise; Haghikia, Arash; Nonhoff, Justus; Bauersachs, Johann (2015-05-07). "Peripartum cardiomyopathy: current management and future perspectives". European Heart Journal. 36 (18): 1090–1097. doi:10.1093/eurheartj/ehv009. ISSN 0195-668X. PMC 4422973. PMID 25636745.{{cite journal}}: CS1 maint: PMC format (link)
  8. ^ Bauersachs, Johann; König, Tobias; van der Meer, Peter; Petrie, Mark C.; Hilfiker-Kleiner, Denise; Mbakwem, Amam; Hamdan, Righab; Jackson, Alice M.; Forsyth, Paul; de Boer, Rudolf A.; Mueller, Christian (2019-07). "Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy". European Journal of Heart Failure. 21 (7): 827–843. doi:10.1002/ejhf.1493. ISSN 1879-0844. PMID 31243866. {{cite journal}}: Check date values in: |date= (help)
  9. ^ a b Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267.
  10. ^ a b Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, Bauersachs J*, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984. *joint senior authors
  11. ^ Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. Circ Res 109, 334-47.
  12. ^ REBIRTH „From Regenerative Biology to Reconstructive Therapy“ (MHH)
  13. ^ REBIRTH Cluster of Excellence
  14. ^ Haghikia A, Podewski E, Berliner D, Sonnenschein K, Fischer D, Angermann CE, Böhm M, Röntgen P, Bauersachs J, Hilfiker-Kleiner D. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin Res Cardiol. 2015 May 31.
  15. ^ Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J (2015). Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 36:1090-1097
  16. ^ Bauersachs J, Arrigo M, Denise Hilfiker-Kleiner DF, ....., Seferovic P, Tavazzi L, Ruschitzka F, Mebazaa A, Sliwa K (2016). Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 18, 1096-105
  17. ^ DIGitoxin to Improve ouTcomes in patients with advanced chronic systolic Heart Failure; EudraCT No: 2013-005326-38
  18. ^ "Oskar-Lapp-Forschungspreis" (in German). Retrieved 2022-03-22.
  19. ^ Eschenhagen, Thomas (2018-08-21). "From basic science to high performance medicine". European Heart Journal. 39 (32): 2919–2921. doi:10.1093/eurheartj/ehy425. ISSN 0195-668X.
  20. ^ "circulation.inforang.com" (PDF).

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Johann_Bauersachs&oldid=1079328262"